



PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~Substitute for form 1449/PTO~~

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shee

1

of

2

Attorney Docket Number FP0617 US

Complete if Known

Application Number	10/566,625
Filing Date	30 January 2006
First Named Inventor	Klaus, Stephen J.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	EP0617 US

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
/00/	BA	WO-97/12855-A1	10 Apr 1997	Vertex Pharmaceuticals		
/00/	BB	WO-03/053997-A2	03 Jul 2003	FibroGen, Inc.		
/00/	BC	WO-2004/004697-A2	15 Jan 2004	Univ Degli Studi di Ferrara		

Examiner Signature /Oluwatosin Ogunbiyi/**Date Considered** 12/28/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

MAR 14 2006

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number	10/566,625
Filing Date	30 January 2006
First Named Inventor	Klaus, Stephen J.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/OO/	CA	DOVER, George J., "Induction of Fetal Hemoglobin Production in Subjects with Sickle Cell Anemia by Oral Sodium Phenylbutyrate," Blood, W.B. Saunders, Philadelphia, PA. U.S., 7/1/1994, Vol. 84, No. 1, pgs. 339-343	
/OO/	CB	PERRINE, Susan P., et al., "Sodium Butyrate Enhances Fetal Globin Gene Expression in Erythroid Progenitors of Patients with Hb SS and Beta Thalassemia," Blood, W.B. Saunders, Philadelphia, PA. U.S., 7/1/89, Vol. 74, No. 1, pgs. 454-459	
/OO/	CC	RODGERS, Griffin P., et al., "Novel Treatment Options in the Severe Beta-Globin Disorders," British Journal of Haematology, Oxford, Great Britain, 1995, Vol. 91, No. 2, pgs. 263-268	

Examiner Signature	/Oluwatosin Ogunbiyi/	Date Considered	12/28/2007
--------------------	-----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

四

1

3

1

Complete if Known

Application Number	10/566,625
Filing Date	30 January 2006
First Named Inventor	Klaus, Stephen J.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	FP0617 US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/00/	BA	WO - 93/18761 - A1	09-30-1993	Child Hosp Med Ctr Nor CA		
/00/	BB	WO - 96/08242 - A3	03-21-1996	Children's Med Ctr Corp		
/00/	BC	WO - 99/24034 - A1	05-20-1999	Children's Med Ctr Corp		
/00/	BD	WO - 03/049686 - A2	06-19-2003	FibroGen, Inc.		

**Examiner
Signature**

/Oluwatosin Ogundubisi/

Date
Considered

12/28/2007

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **¹Applicant's unique citation designation number (optional).** **²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.** **³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).** **⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.** **⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.** **⁶Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

5

Application Number	10/566,625
Filing Date	30 January 2006
First Named Inventor	Klaus, Stephen J.
Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number

FP0617 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/00/	CA	ADDAE, S., et al., "Survival of Patients With Sickle Cell Anemia Living at High Altitude," South Med J, 1990, Vol. 83, No. 4, p. 487.	
	CB	AL-KHATTI, A., et al., "Erythropoietin Stimulates F-Reticulocyte Formation in Sickle Cell Anemia," Trans. Assoc. Am. Physicians, 1988, Vol. 101, pp. 54-61.	
	CC	BARD, Harry, et al., "Hypoxemia and Increased Fetal Hemoglobin Synthesis," J Pediatrics, 1994, Vol. 124, No. 6, pp. 941-943.	
	CD	BICKEL, Martin, et al., "Selective Inhibition of Hepatic Collagen Accumulation in Experimental Liver Fibrosis in Rats by a New Prolyl 4-Hydroxylase Inhibitor," Hepatology, 1998, Vol. 28, No. 2, pp. 404-411.	
	CE	BLAU, Anthony, et al., "Fetal Hemoglobin Induction With Butyric Acid: Efficacy and Toxicity," Blood, 1993, Vol. 81, No. 2, pp. 529-537.	
	CF	CHARACHE, Samuel, et al., "Hydroxyurea-Induced Augmentation of Fetal Hemoglobin Production in Patients With Sickle Cell Anemia," Blood, 1987, Vol. 69, No. 1, pp. 109-116.	
	CG	CHARACHE, Samuel, et al., "Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia," N Engl J Med, 1995, Vol. 332, No. 20, pp. 1317-1322.	
	CH	COKIC, Vladan P., et al., "Hydroxyurea Induces Fetal Hemoglobin by the Nitric Oxide-Dependent Activation of Soluble Guanylyl Cyclase," J Clin Invest, 2003, Vol. 111, No. 2, pp. 231-239.	
	CI	CONSTANTOULAKIS, P., et al., "On the Induction of Fetal Hemoglobin by Butyrates: In Vivo and In Vitro Studies With Sodium Butyrate and Comparison of Combination Treatments With 5-AzaC and AraC," Blood, 1989, Vol. 74, No. 6, pp. 1963-1971	
↓	CJ	DESIMONE, Joseph, et al., "Stimulation of Fetal Hemoglobin Synthesis in Baboons by Hemolysis and Hypoxia," Proc. Natl. Acad. Sci. USA, 1978, Vol. 75, No. 6, pp. 2937-2940.	

Examiner Signature	/Oluwatosin Ogunbiyi/	Date Considered	12/28/2007
--------------------	-----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>					
Sheet	3	of	5	Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/OO/	CK	DESIMONE, Joseph, et al., "Maintenance of Fetal Hemoglobin (HbF) Elevations in the Baboon by Prolonged Erythropoietic Stress," Blood, 1982, Vol. 60, No. 2, pp. 519-523.	
	CL	DESIMONE, Joseph, et al., "Maintenance of Elevated Fetal Hemoglobin Levels by Decitabine During Dose Interval Treatment of Sickle Cell Anemia," Blood, 2002, Vol. 99, No. 11, pp. 3905-3908.	
	CM	FIBACH, Eitan, et al., "Enhanced Fetal Hemoglobin Production by Phenylacetate and 4-Phenylbutyrate in Erythroid Precursors Derived From Normal Donors and Patients With Sickle Cell Anemia and G- Thalassemia," Blood, 1993, Vol. 82, No. 7, pp. 2203-2209.	
	CN	FIBACH, Eitan, et al., "Mithramycin Induces Fetal Hemoglobin Production in Normal and Thalassemic Human Erythroid Precursor Cells," Blood, 2003, Vol. 102, No. 4, pp. 1276-1281.	
	CO	FRANKLIN, Trevor J., et al., "Approaches to the Design of Anti-Fibrotic Drugs," Biochem Soc Trans, 1991, Vol. 19, pp. 812-815.	
	CP	FRANKLIN, Trevor J., et al., "Inhibition of Prolyl 4-Hydroxylase In Vitro and In Vivo by Members of a Novel Series of Phenanthrolinones," Biochem J, 2001, Vol. 353, pp. 333-338.	
	CQ	FRIEDMAN, Lisa, et al., "Prolyl 4-Hydroxylase is Required for Viability and Morphogenesis in Caenorhabditis elegans," PNAS, 2000, Vol. 97, No. 9, pp. 4736-4741.	
	CR	GABBIANELLI, Marco, et al., "Granulocyte-Macrophage Colony-Stimulating Factor Reactivates Fetal Hemoglobin Synthesis in Erythroblast Clones From Normal Adults," Blood, 1989, Vol. 74, No. 8, pp. 2657-2667.	
	CS	GABBIANELLI, Marco, et al., "Hemoglobin Switching in Unicellular Erythroid Culture of Sibling Erythroid Burst-Forming Units: Kit Ligand Induces a Dose-Dependent Fetal Hemoglobin Reactivation Potentiated by Sodium Butyrate," Blood, 2000, Vol. 95, No. 11, pp. 3555-3561	
	CT	JIANG, Jinjie, et al., "In Vivo Production of Nitric Oxide in Rats After Administration of Hydroxyurea," Mol Pharmacol, 1997, Vol. 52, pp. 1081-1086	

Examiner Signature	/Oluwatosin Ogunbiyi/	Date Considered	12/28/2007
--------------------	-----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/566,625
				Filing Date	30 January 2006
				First Named Inventor	Klaus, Stephen J.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	4	of	5	Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/00/	CU	KIVIRIKKO, Kari I., et al., "Prolyl 4-Hydroxylases and Their Protein Disulfide Isomerase Subunit," <i>Matrix Biol</i> , 1997, Vol. 16, pp. 357-368.				
	CV	LETVIN, Norman L., et al., "Augmentation of Fetal-Hemoglobin Production in Anemic Monkeys by Hydroxyurea," <i>N Engl J Med</i> , 1984, Vol. 310, No. 14, pp. 869-873.				
	CW	LEY, Timothy J., et al., "Induction of Hemoglobin F Synthesis in Patients With β-Thalassemia," <i>Annu Rev Med</i> , 1985, Vol. 36, pp. 485-498.				
	CX	LEY, Timothy J., et al., "5-Azacytidine Selectively Increases γ-globin Synthesis in a Patient With β+ Thalassemia," <i>N Engl J Med</i> , 1982, Vol. 307, No. 24, pp. 1469-1475.				
	CY	MAJAMAA, Kari, et al., "The 2-Oxoglutarate Binding Site of Prolyl 4-Hydroxylase," <i>Eur J Biochem</i> , 1984, Vol. 138, pp. 239-245.				
	CZ	MAJAMAA, Kari, et al., "Differences Between Collagen Hydroxylases and 2-Oxoglutarate Dehydrogenase in Their Inhibition by Structural Analogues of 2-Oxyglutarate," <i>Biochem J</i> , 1985, Vol. 229, pp. 127-133.				
	CAA	MIGLIACCIO, Anna R., et al., "Influence of Recombinant Hematopoietin and of Fetal Bovine Serum on the Globin Synthetic Pattern of Human BFUe," <i>Blood</i> , 1990, Vol. 76, No. 6, pp. 1150-1157.				
	CBB	MILLER, Barbara A., et al., "High Fetal Hemoglobin Production in Sickle Cell Anemia in the Eastern Province of Saudi Arabia Is Genetically Determined," <i>Blood</i> , 1986, Vol. 67, No. 5, pp. 1404-1410.				
	CCC	MILLER, Barbara A., et al., "Influence of Steel Factor on Hemoglobin Synthesis in Sickle Cell Disease," <i>Blood</i> , 1992, Vol. 79, No. 7, pp. 1861-1868.				
↓	CDD	PARTINGTON, G.A., et al., "Human Globin Gene Transcription in Injected Xenopus Oocytes: Enhancement by Sodium Butyrate," <i>EMBO J</i> , 1984, Vol. 3, No. 12, pp. 2787-2792.				

Examiner Signature	/Oluwatosin Ogunbiyi/	Date Considered	12/28/2007
--------------------	-----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/566,625
				Filing Date	30 January 2006
				First Named Inventor	Klaus, Stephen J.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	5	of	5	Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/00/	CEE	PEMBREY, M.E., et al., "Fetal Haemoglobin Production and the Sickle Gene in the Oases of Eastern Saudi Arabia," Br J Haematology, 1978, Vol. 40, pp. 415-429.			
	CFF	PERRINE, Susan P., et al., "Butyric Acid Analogues Augment γ -Globin Gene Expression in Neonatal Erythroid Progenitors," Biochem Biophys Res Comm, 1987, Vol. 148, No. 2, pp. 694-700.			
	CGG	PERRINE, Susan P., et al., "Butyrate Infusions in the Ovine Fetus Delay the Biologic Clock for Globin Gene Switching," Proc. Natl. Acad. Sci. USA, 1988, Vol. 85, pp. 8540-8542.			
	CHH	PERRINE, Susan P., et al., "A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β -Globin Disorders," N Engl J Med, 1993, Vol. 328, No. 2, pp. 81-86.			
	CII	RODGERS, Griffin P., et al., "Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease," N Engl J Med, 1993, Vol. 328, No. 2, pp. 73-80.			
	CJJ	SAFAYA, S., et al., "Augmentation of γ -Globin Gene Promoter Activity by Carboxylic Acids and Components of the Human β -Globin Locus Control Region," Blood, 1994, Vol. 84, No. 11, pp. 3929-3935.			
	CKK	STAMATOYANNOPOULUS, George, et al., "Fetal-Hemoglobin Induction by Acetate, a Product of Butyrate Catabolism," Blood, 1994, Vol. 84, No. 9, pp. 3198-3204.			
	CLL	WEINBERG, R.S., et al., "Low Oxygen Enhances Sickle and Normal Erythropoiesis and Fetal Hemoglobin Synthesis In Vitro," Hemoglobin, 1995, Vol. 19, No. 5, pp. 263-275.			
	CMM	WELFORD, Richard W.D., et al., "The Selectivity and Inhibition of AlkB," J Bio Chem, 2003, Vol. 278, No. 12, pp. 10157-10161.			
▼	CNN	WOOD, W.G., et al., "Developmental Genetics of the Human Haemoglobins," Biochem J., 1983, Vol. 215, pp. 1-10.			

Examiner Signature	/Oluwatosin Ogunbiyi/	Date Considered	12/28/2007
--------------------	-----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.